Associated Papers
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Pharmacogenomics in Orofacial Clefts Care: Insights from Whole-Genome Sequencing of Case-Parents Trios.
Poku-Adusei E et al.
Journal of Personalized Medicine, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas.
Wolthuis DFGJ et al.
European Journal of Human Genetics : Ejhg, 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro.
Bao SS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
Germline loss-of-function variant in the E3 ubiquitin ligase TRAF2 in a young adult patient with medulloblastoma: a case report.
Vo JN et al.
Acta Neuropathologica Communications, 2024
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
Roncato R et al.
Jama Network Open, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs.
Manson LEN et al.
European Journal of Human Genetics : Ejhg, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Genetic variation of CYP2C9 gene and its correlation with cardiovascular disease risk factors.
Rasool GS et al.
Molecular Biology Reports, 2024
Identification of the effects of pathogenic genetic variations of human CYP2C9 and CYP2D6: an in silico approach.
Avsar O
Nucleosides, Nucleotides & Nucleic Acids, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Beyond Single Diagnosis: Exploring Multidiagnostic Realities in Pediatric Patients through Genome Sequencing.
Guo F et al.
Human Mutation, 2024
Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen.
Yuan LJ et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia.
Giraldo-Ocampo S et al.
Medicine, 2023
Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences.
Zhou Y et al.
Human Genomics, 2023
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R et al.
Pharmacogenomics, 2023
Pharmacogenomic implications of the differential distribution of CYP2C9 metabolic phenotypes among Latin American populations.
Suarez-Kurtz G
Frontiers in Pharmacology, 2023
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E et al.
Plos One, 2022
Ethnic Diversity and Warfarin Pharmacogenomics.
Asiimwe IG et al.
Frontiers in Pharmacology, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.
Ndadza A et al.
Journal of Thrombosis and Haemostasis : Jth, 2021
Pharmacogenetic determinants of warfarin in the Indian population.
Naushad SM et al.
Pharmacological Reports : Pr, 2021
Insights into the Genetic Variations of Human Cytochrome P450 2C9: Structural Analysis, Characterization and Comparison.
Parikh SJ et al.
International Journal of Molecular Sciences, 2021
PharmVar GeneFocus: CYP2C9.
Sangkuhl K et al.
Clinical Pharmacology and Therapeutics, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders.
Zampatti S et al.
Journal of Personalized Medicine, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease.
Cacabelos R et al.
Pharmaceuticals (basel, Switzerland), 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations.
Nizamuddin S et al.
Pharmacogenomics and Personalized Medicine, 2021
The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients.
Akdeniz CS et al.
Future Cardiology, 2020
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Zhang L et al.
Clinical and Translational Science, 2020
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
El Rouby N et al.
Clinical and Translational Science, 2020
Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
Caspar SM et al.
International Journal of Molecular Sciences, 2020
Cytochrome P450 2C9 polymorphism: Effect of amino acid substitutions on protein flexibility in the presence of tamoxifen.
Manish M et al.
Computational Biology and Chemistry, 2020
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF et al.
Drug Design, Development and Therapy, 2020
Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson's Disease.
Cacabelos R et al.
Planta Medica, 2019
Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH et al.
Clinical Pharmacology and Therapeutics, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
Langaee T et al.
Genetic Testing and Molecular Biomarkers, 2019